HTA217 Reimbursement of Drugs for Rare Diseases in Canada: Do Treatment Cost and Cost-Effectiveness Ratio Correlate With Epidemiologic Factors?
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.1675
https://www.valueinhealthjournal.com/article/S1098-3015(22)03880-3/fulltext
Title :
HTA217 Reimbursement of Drugs for Rare Diseases in Canada: Do Treatment Cost and Cost-Effectiveness Ratio Correlate With Epidemiologic Factors?
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)03880-3&doi=10.1016/j.jval.2022.09.1675
First page :
Section Title :
Open access? :
No
Section Order :
11228